Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet); Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC); European Society of Mycobacteriology (ESM); European Respiratory Society (ERS)

doi:https://doi.org/10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and, Tuberculosis Network European Trials group (TBnet), Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS)

Research output: Contribution to journal › Comment/Letter to the editor › Academic

16 Citations (Scopus)

Original language	English
Article number	2200388
Pages (from-to)	1-3
Number of pages	3
Journal	European respiratory journal
Volume	59
Issue number	5
DOIs	https://doi.org/10.1183/13993003.00388-2022
Publication status	Published - 1 May 2022

Keywords

Antibiotics, Antitubercular/therapeutic use
Antitubercular Agents/therapeutic use
Drug Therapy, Combination
Europe
Humans
Rifampin/analogs & derivatives
Tuberculosis/drug therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1183/13993003.00388-2022

Cite this

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and, Tuberculosis Network European Trials group (TBnet), Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), & European Respiratory Society (ERS) (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European respiratory journal, 59(5), 1-3. Article 2200388. https://doi.org/10.1183/13993003.00388-2022

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and ; Tuberculosis Network European Trials group (TBnet) ; Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC) et al. / Rifapentine access in Europe : growing concerns over key tuberculosis treatment component. In: European respiratory journal. 2022 ; Vol. 59, No. 5. pp. 1-3.

@article{3aa150538488485a90385a555d959ba9,

title = "Rifapentine access in Europe: growing concerns over key tuberculosis treatment component",

keywords = "Antibiotics, Antitubercular/therapeutic use, Antitubercular Agents/therapeutic use, Drug Therapy, Combination, Europe, Humans, Rifampin/analogs & derivatives, Tuberculosis/drug therapy",

author = "Lorenzo Guglielmetti and Gunar G{\"u}nther and Claude Leu and Daniela Cirillo and Raquel Duarte and Garcia-Basteiro, {Alberto L.} and Delia Goletti and Mateja Jankovic and Liga Kuksa and Maurer, {Florian P.} and Fr{\'e}d{\'e}ric M{\'e}cha{\"i} and Simon Tiberi and {van Leth}, Frank and Nicolas Veziris and {Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and} and {Tuberculosis Network European Trials group (TBnet)} and Christoph Lange and {Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC)} and {European Society of Mycobacteriology (ESM)} and {European Respiratory Society (ERS)} and Hasan Hafizi and Naira Khachatryan and Harut Aroyan and Eduard Kabasakalyan and Michael Knappik and Alena Skrahina and Dzmitry Klimuk and Alena Nikolenka and Inge Muylle and Vladimir Milanov and Desislava Velkovska and Neli Tarinska and Elizabeta Bachiyska and Despo Pieridou and Tonia Adamide and Nicos Nicolaou and Martina Vasakova and Mariia Sukholytka and Emilia Kopeck{\`a} and Beata Polakova and Anderson, {Aase Bengard} and Folkvardsen, {Dorte Bek} and Erik Svensson and Manfred Danilovits and Tiina Kummik and Tuula Vasankari and Mathilde Fr{\'e}chet-Jachym and Audrey Nahmiash and Tamar Togonidze and Zaza Avaliani and Inga Kinkladze and Rusudan Aspindzelashvili and Teona Bichashvili and Gulnazi Losaberidze and Tsitsino Merabishvili",

note = "Funding Information: Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry.",

year = "2022",

month = may,

day = "1",

doi = "https://doi.org/10.1183/13993003.00388-2022",

language = "English",

volume = "59",

pages = "1--3",

journal = "European respiratory journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "5",

}

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and, Tuberculosis Network European Trials group (TBnet), Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM) & European Respiratory Society (ERS) 2022, 'Rifapentine access in Europe: growing concerns over key tuberculosis treatment component', European respiratory journal, vol. 59, no. 5, 2200388, pp. 1-3. https://doi.org/10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. / Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet); Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC) et al.
In: European respiratory journal, Vol. 59, No. 5, 2200388, 01.05.2022, p. 1-3.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Rifapentine access in Europe

T2 - growing concerns over key tuberculosis treatment component

AU - Guglielmetti, Lorenzo

AU - Günther, Gunar

AU - Leu, Claude

AU - Cirillo, Daniela

AU - Duarte, Raquel

AU - Garcia-Basteiro, Alberto L.

AU - Goletti, Delia

AU - Jankovic, Mateja

AU - Kuksa, Liga

AU - Maurer, Florian P.

AU - Méchaï, Frédéric

AU - Tiberi, Simon

AU - van Leth, Frank

AU - Veziris, Nicolas

AU - Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and

AU - Tuberculosis Network European Trials group (TBnet)

AU - Lange, Christoph

AU - Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC)

AU - European Society of Mycobacteriology (ESM)

AU - European Respiratory Society (ERS)

AU - Hafizi, Hasan

AU - Khachatryan, Naira

AU - Aroyan, Harut

AU - Kabasakalyan, Eduard

AU - Knappik, Michael

AU - Skrahina, Alena

AU - Klimuk, Dzmitry

AU - Nikolenka, Alena

AU - Muylle, Inge

AU - Milanov, Vladimir

AU - Velkovska, Desislava

AU - Tarinska, Neli

AU - Bachiyska, Elizabeta

AU - Pieridou, Despo

AU - Adamide, Tonia

AU - Nicolaou, Nicos

AU - Vasakova, Martina

AU - Sukholytka, Mariia

AU - Kopeckà, Emilia

AU - Polakova, Beata

AU - Anderson, Aase Bengard

AU - Folkvardsen, Dorte Bek

AU - Svensson, Erik

AU - Danilovits, Manfred

AU - Kummik, Tiina

AU - Vasankari, Tuula

AU - Fréchet-Jachym, Mathilde

AU - Nahmiash, Audrey

AU - Togonidze, Tamar

AU - Avaliani, Zaza

AU - Kinkladze, Inga

AU - Aspindzelashvili, Rusudan

AU - Bichashvili, Teona

AU - Losaberidze, Gulnazi

AU - Merabishvili, Tsitsino

N1 - Funding Information: Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry.

PY - 2022/5/1

Y1 - 2022/5/1

KW - Antibiotics, Antitubercular/therapeutic use

KW - Antitubercular Agents/therapeutic use

KW - Drug Therapy, Combination

KW - Europe

KW - Humans

KW - Rifampin/analogs & derivatives

KW - Tuberculosis/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85130397640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130397640&partnerID=8YFLogxK

U2 - https://doi.org/10.1183/13993003.00388-2022

DO - https://doi.org/10.1183/13993003.00388-2022

M3 - Comment/Letter to the editor

C2 - 35589114

SN - 0903-1936

VL - 59

SP - 1

EP - 3

JO - European respiratory journal

JF - European respiratory journal

IS - 5

M1 - 2200388

ER -

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and, Tuberculosis Network European Trials group (TBnet), Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European respiratory journal. 2022 May 1;59(5):1-3. 2200388. doi: https://doi.org/10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Keywords

UN SDGs

Access to Document

Other files and links

Cite this